Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FDY 5301 (Primary)
  • Indications Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms IOCYTE AMI-3
  • Sponsors Faraday Pharmaceuticals

    • Most Recent Events

    • 11 Jun 2024 According to a Faraday Pharmaceuticals media release, trial is being conducted under a Special Protocol Assessment agreement reached with the FDA.
    • 11 Jun 2024 According to a Faraday Pharmaceuticals media release, after a recent, planned interim analysis of safety and efficacy data from over 1,500 patients followed up for at least 28 days, the trial's independent data monitoring committee recommended completing the trial without modification.
    • 11 Jun 2024 Status changed from recruiting to active, no longer recruiting, according to a Faraday Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top